Healthcare Analytical Testing Services Market Size by Type (Biomarker Testing, Stability Testing, Raw Material Testing, Batch-release Testing, Cleaning Validation), End User (Pharmaceutical Companies, Medical Device Companies) & Region - Global Forecast to 2029
The Healthcare analytical testing services Market is projected to reach USD 12.6 billion by 2029 from USD 7.4 billion in 2024, at a CAGR of 11.2% during the forecast period. The growth of the healthcare analytical testing services market is fueled by increasing demand across industries for quality assurance and regulatory compliance. Challenges in developing precise analytical techniques provide opportunities for service providers, while government initiatives encourage investment and innovation. These factors drive market expansion globally, alongside trends such as outsourcing due to pricing concerns and the development of innovative medicines. Expansion into new locations also boosts demand for specific tests, further driving the need for healthcare analytical testing services.
“Biohealthcare analytical testing services segment accounted for a substantial share of the healthcare analytical testing services market, by type in 2023.”
The Biohealthcare analytical testing services segment is expected to account for the largest share of 37.1% of the global Healthcare analytical testing services Market in 2023. It is projected to grow at the highest CAGR of 10.7% during the forecast period. The healthcare analytical testing services market is segmented by type into various categories, including bioanalytical testing, physical characterization, method development and validation, stability testing, batch-release testing, raw material testing, microbial testing, genomic services, and environmental monitoring services. In 2023, the biohealthcare analytical testing services segment stood out as the largest, primarily due to its comprehensive offerings tailored to different drug types like vaccines, small molecules, and biologics. This extensive range of services meets the diverse requirements of pharmaceutical and biopharmaceutical companies, thereby driving the segment's substantial market share.
“The cell-based assays segment accounted for the largest share in the healthcare analytical testing services market”
Based on bioanalytical service types type, the market encompasses cell-based assays, virology testing, biomarker testing, immunogenicity and neutralizing antibody testing, pharmacokinetic testing, and other biohealthcare analytical testing services. In 2023, the cell-based assays segment emerged as the market leader. This dominance is attributed to the growing preference for cell-based assays in high-throughput screening, as they offer pertinent in vivo biological insights compared to biochemical assays. This advantage accelerates the drug discovery process, thus contributing to the segment's prominence.
“North America to witness the substantial growth rate during the forecast period.”
North America commands the largest share in the healthcare analytical testing services market, outstripping other regions such as Europe, Asia Pacific, Latin America, and the Middle East & Africa. This dominance is primarily fueled by the burgeoning number of biopharmaceutical and pharmaceutical companies based in the United States. Moreover, the US market benefits from the strong foothold of well-established players, which further propels the market's growth trajectory. The region's advanced infrastructure, supportive regulatory environment, and emphasis on research and development also contribute significantly to its leadership position in the global healthcare analytical testing services market.
The break-down of primary participants is as mentioned below:
The prominent players in the global healthcare analytical testing services market include Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Medpace Holdings, Inc. (US), LGC Limited (Cinven) (UK), Parexel International Corporation (US), Celerion (US). Pharmaron (China), BioAgilytix Labs (US), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK), Thermo Fisher Scientific, Inc. (US), Pace Analytical Services LLC (US), Intertek Group plc (UK), IQVIA Inc. (US), Merck KGaA (Germany), Source BioScience (UK), Almac Group (UK), ICON Plc (Ireland), Frontage Laboratories, Inc. (US), STERIS Plc (US), Sartorius AG (Germany), ALS Life Science (US), and Syneos Health, INC (US).
Research Coverage:
The report analyzes the Healthcare analytical testing services Market and aims to estimate the market size and future growth potential of various market segments, based on type, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
“Biohealthcare analytical testing services segment accounted for a substantial share of the healthcare analytical testing services market, by type in 2023.”
The Biohealthcare analytical testing services segment is expected to account for the largest share of 37.1% of the global Healthcare analytical testing services Market in 2023. It is projected to grow at the highest CAGR of 10.7% during the forecast period. The healthcare analytical testing services market is segmented by type into various categories, including bioanalytical testing, physical characterization, method development and validation, stability testing, batch-release testing, raw material testing, microbial testing, genomic services, and environmental monitoring services. In 2023, the biohealthcare analytical testing services segment stood out as the largest, primarily due to its comprehensive offerings tailored to different drug types like vaccines, small molecules, and biologics. This extensive range of services meets the diverse requirements of pharmaceutical and biopharmaceutical companies, thereby driving the segment's substantial market share.
“The cell-based assays segment accounted for the largest share in the healthcare analytical testing services market”
Based on bioanalytical service types type, the market encompasses cell-based assays, virology testing, biomarker testing, immunogenicity and neutralizing antibody testing, pharmacokinetic testing, and other biohealthcare analytical testing services. In 2023, the cell-based assays segment emerged as the market leader. This dominance is attributed to the growing preference for cell-based assays in high-throughput screening, as they offer pertinent in vivo biological insights compared to biochemical assays. This advantage accelerates the drug discovery process, thus contributing to the segment's prominence.
“North America to witness the substantial growth rate during the forecast period.”
North America commands the largest share in the healthcare analytical testing services market, outstripping other regions such as Europe, Asia Pacific, Latin America, and the Middle East & Africa. This dominance is primarily fueled by the burgeoning number of biopharmaceutical and pharmaceutical companies based in the United States. Moreover, the US market benefits from the strong foothold of well-established players, which further propels the market's growth trajectory. The region's advanced infrastructure, supportive regulatory environment, and emphasis on research and development also contribute significantly to its leadership position in the global healthcare analytical testing services market.
The break-down of primary participants is as mentioned below:
- By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
- By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
- By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, ROW-10%
The prominent players in the global healthcare analytical testing services market include Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Medpace Holdings, Inc. (US), LGC Limited (Cinven) (UK), Parexel International Corporation (US), Celerion (US). Pharmaron (China), BioAgilytix Labs (US), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK), Thermo Fisher Scientific, Inc. (US), Pace Analytical Services LLC (US), Intertek Group plc (UK), IQVIA Inc. (US), Merck KGaA (Germany), Source BioScience (UK), Almac Group (UK), ICON Plc (Ireland), Frontage Laboratories, Inc. (US), STERIS Plc (US), Sartorius AG (Germany), ALS Life Science (US), and Syneos Health, INC (US).
Research Coverage:
The report analyzes the Healthcare analytical testing services Market and aims to estimate the market size and future growth potential of various market segments, based on type, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
- Analysis of Market Dynamics (Stringent regulatory landscape, growing focus on analytical testing of bilogics and biomilars, rising investments in pharma and biopharma R & D), restraints (Increasing Preassure on market players due to rising cost and market competition), opportunities (Adoption of new technologies, supporting government initiatives), and challenges (increasing need for improvement of sentsitivity of bioanalytical methods)
- Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new service launches in the Healthcare analytical testing services market.
- Market Development: Comprehensive information on the lucrative emerging markets, component, demographics , end-user, and region.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the healthcare analytical testing services market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the healthcare analytical testing services market like Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK) among others.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.2.2 MARKET SEGMENTATION
FIGURE 1 MARKETS COVERED
1.2.3 REGIONS COVERED
FIGURE 2 REGIONAL SEGMENTATION
1.2.4 YEARS CONSIDERED
1.3 CURRENCY CONSIDERED
1.4 LIMITATIONS
1.4.1 METHODOLOGY-RELATED LIMITATIONS
1.4.2 SCOPE-RELATED LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH METHODOLOGY DESIGN
FIGURE 3 RESEARCH DESIGN
2.2.1 SECONDARY RESEARCH
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
FIGURE 4 PRIMARY SOURCES
2.2.2.1 Key data from primary sources
2.2.2.2 Insights from primary experts
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION METHODOLOGY
FIGURE 7 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 8 REVENUE SHARE ANALYSIS: COMPANY ILLUSTRATION
FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 10 TOP-DOWN APPROACH
FIGURE 11 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 12 CAGR PROJECTIONS
2.4 DATA TRIANGULATION PROCEDURE
FIGURE 13 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ESTIMATION
2.6 STUDY ASSUMPTIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT ANALYSIS
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 14 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 16 PHYSICAL CHARACTERIZATION TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 17 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
4 PREMIUM INSIGHTS
4.1 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET OVERVIEW
FIGURE 19 GROWING ADOPTION OF OUTSOURCED ANALYTICAL TESTING SERVICES BY PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES TO DRIVE GROWTH
4.2 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE AND COUNTRY (2023)
FIGURE 20 BIOANALYTICAL TESTING SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2023
4.3 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 CHINA, INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 REGIONAL MIX: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET (2022–2029)
FIGURE 22 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD (2022–2029)
4.5 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEVELOPED VS. EMERGING ECONOMIES (2024 VS. 2029)
FIGURE 23 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 24 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Stringent regulatory guidelines
5.2.1.2 Growing focus on analytical testing of biologics & biosimilars
TABLE 2 PATENT EXPIRY OF BEST-SELLING BIOLOGICS
5.2.1.3 Increasing outsourcing of analytical testing by pharmaceutical & medical device companies
5.2.1.4 Increasing number of clinical trials
FIGURE 25 INCREASING NUMBER OF CLINICAL TRIALS WORLDWIDE (2004–2024)
FIGURE 26 PERCENTAGE OF REGISTERED STUDIES BY LOCATION (AS OF MARCH 08, 2024)
5.2.1.5 Growing R&D expenditure in pharmaceutical & biopharmaceutical industry
FIGURE 27 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2002–2022
5.2.1.6 Rising acceptance of quality-by-design approach in pharmaceutical research & manufacturing
TABLE 3 IMPACT ANALYSIS: DRIVERS
5.2.2 RESTRAINTS
5.2.2.1 Increasing pressure on market players due to rising costs and market competition
TABLE 4 IMPACT ANALYSIS: RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.3.1 Adoption of new techniques and technologies
5.2.3.2 Growing focus on emerging economies
TABLE 5 IMPACT ANALYSIS: OPPORTUNITIES
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled professionals
5.2.4.2 Specific requirements for innovative formulations and medical devices
5.2.4.3 Need to improve sensitivity of bioanalytical methods
TABLE 6 IMPACT ANALYSIS: CHALLENGES
5.3 ECOSYSTEM ANALYSIS
TABLE 7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ROLE IN ECOSYSTEM
FIGURE 28 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ECOSYSTEM ANALYSIS
5.4 VALUE CHAIN ANALYSIS
FIGURE 29 VALUE CHAIN ANALYSIS
5.5 CASE STUDY ANALYSIS
5.5.1 UNLOCKING BIOPHARMACEUTICAL DEVELOPMENT POTENTIAL THROUGH OUTSOURCING ANALYTICAL TESTING
5.5.2 REVOLUTIONIZING PHARMACEUTICAL TESTING: A CASE STUDY IN ANALYTICAL TESTING EVOLUTION
5.6 PORTER’S FIVE FORCES ANALYSIS
TABLE 8 PORTER’S FIVE FORCES ANALYSIS
FIGURE 30 PORTER’S FIVE FORCES ANALYSIS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 BARGAINING POWER OF SUPPLIERS
5.6.3 INTENSITY OF COMPETITIVE RIVALRY
5.6.4 BARGAINING POWER OF BUYERS
5.6.5 THREAT OF SUBSTITUTES
5.7 REGULATORY LANDSCAPE
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.2 REGULATORY ANALYSIS
TABLE 14 ICH QUALITY GUIDELINES FOR PHARMACEUTICAL GMPS
TABLE 15 OVERVIEW OF GUIDELINES OF LABORATORY SERVICES
5.7.3 NORTH AMERICA
5.7.4 EUROPE
TABLE 16 DEVELOPMENT OF GLP ACROSS COUNTRIES
TABLE 17 REGULATORY AUTHORITIES AND LAUNCH OF GLP MONITORING PROGRAMS IN EUROPEAN COUNTRIES
5.7.5 ASIA PACIFIC
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 31 REVENUE SHIFT AND NEW POCKETS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
5.9 KEY CONFERENCES & EVENTS, 2024–2025
TABLE 18 HEALTHCARE ANALYTICAL TESTING MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.10 INVESTMENT AND FUNDING SCENARIO
FIGURE 32 NUMBER OF INVESTOR DEALS IN HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY KEY PLAYER, 2018–2022
FIGURE 33 VALUE OF INVESTOR DEALS IN HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY KEY PLAYER, 2018-2022
5.11 KEY STAKEHOLDERS & BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
5.11.2 BUYING CRITERIA
FIGURE 35 KEY BUYING CRITERIA FOR END USERS
TABLE 20 KEY BUYING CRITERIA FOR END USERS
6 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 21 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
6.2 BIOANALYTICAL TESTING
TABLE 22 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 23 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1 PHARMACOKINETIC & TOXICOKINETIC TESTING
6.2.1.1 Increasing number of clinical trials for drug development to propel growth
TABLE 24 PHARMACOKINETIC TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.2 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING
6.2.2.1 Increasing requirement for drug safety approvals to support market growth
TABLE 25 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.3 BIOMARKER TESTING
6.2.3.1 Rising need for specialized drug development to drive market
TABLE 26 BIOMARKER TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.4 BIOASSAY TESTING
6.2.4.1 Growing adoption of high-content screening for cytotoxicity testing to fuel growth
TABLE 27 BIOASSAY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.5 OTHER BIOANALYTICAL TESTING SERVICES
TABLE 28 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3 PHYSICAL CHARACTERIZATION
TABLE 29 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 30 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.1 LASER PARTICLE SIZE ANALYSIS
6.3.1.1 Growing importance of particle size analysis in manufacturing pharmaceutical dosage forms to drive market
TABLE 31 LASER PARTICLE SIZE ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.2 THERMAL ANALYSIS
6.3.2.1 Advancements in thermal analysis techniques to support growth
TABLE 32 THERMAL ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.3 OPTICAL CHARACTERIZATION
6.3.3.1 Growing complexity of biological structures to contribute to growth
TABLE 33 OPTICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.4 SURFACE AREA ANALYSIS
6.3.4.1 Growing need for surface analysis to streamline drug development processes to fuel growth
TABLE 34 SURFACE AREA ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.5 OTHER PHYSICAL CHARACTERIZATION SERVICES
TABLE 35 OTHER PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4 METHOD DEVELOPMENT & VALIDATION
TABLE 36 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 37 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.1 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION
6.4.1.1 Growing development of parenterally administered drugs and biologic products to drive market
TABLE 38 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.2 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION
6.4.2.1 Rising emphasis on impurity testing to boost market
TABLE 39 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.3 STABILITY-INDICATING METHOD VALIDATION
6.4.3.1 Need to ensure safety and efficacy of therapeutic drugs to spur growth
TABLE 40 STABILITY-INDICATING METHOD VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.4 CLEANING VALIDATION & METHOD DEVELOPMENT
6.4.4.1 Growing needs to evaluate cleaning practices and ensure complete decontamination to fuel growth
TABLE 41 CLEANING VALIDATION & METHOD DEVELOPMENT SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.5 ANALYTICAL STANDARD CHARACTERIZATION
6.4.5.1 Growing importance of analytical standard characterization in drug development to support market
TABLE 42 ANALYTICAL STANDARD CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.6 TECHNICAL CONSULTING
6.4.6.1 Need for regulatory approvals for drug development to drive market
TABLE 43 TECHNICAL CONSULTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.7 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES
TABLE 44 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5 RAW MATERIAL TESTING
TABLE 45 RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 46 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5.1 COMPLETE COMPENDIAL TESTING
6.5.1.1 Need to determine efficacy and safety of therapeutic products to drive growth
TABLE 47 COMPLETE COMPENDIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5.2 CONTAINER TESTING
6.5.2.1 Need to optimize sealing and evaluate temperature impact to fuel growth
TABLE 48 CONTAINER TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5.3 HEAVY METAL TESTING
6.5.3.1 Implementation of various techniques and technologies for heavy metal testing to aid growth
TABLE 49 HEAVY METAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5.4 WATER CONTENT ANALYSIS
6.5.4.1 Need to check for water content in pharmaceutical products to support growth
TABLE 50 WATER CONTENT ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5.5 OTHER RAW MATERIAL TESTING SERVICES
TABLE 51 OTHER RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6 BATCH-RELEASE TESTING SERVICES
TABLE 52 BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 53 BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6.1 DISSOLUTION TESTING
6.6.1.1 Wide usage of dissolution testing in formulation development and manufacturing to drive growth
TABLE 54 DISSOLUTION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6.2 ELEMENTAL IMPURITY TESTING
6.6.2.1 Need to minimize cost of in-house analysis and labor to fuel growth
TABLE 55 ELEMENTAL IMPURITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6.3 DISINTEGRATION TESTING
6.6.3.1 Need to ensure batch-to-batch consistency of pharmaceutical dosage forms to promote growth
TABLE 56 BREAKDOWN OF DISINTEGRATION METHODS AND IMMERSION MEDIA
TABLE 57 DISINTEGRATION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6.4 HARDNESS TESTING
6.6.4.1 Need to assess manufacturability and compactness of pharmaceutical formulations to ensure growth
TABLE 58 HARDNESS TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6.5 FRIABILITY TESTING
6.6.5.1 Need to measure resistance of tablets and granules to abrasion or fracture to support market
TABLE 59 FRIABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6.6 OTHER BATCH-RELEASE TESTING SERVICES
TABLE 60 OTHER BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7 STABILITY TESTING
TABLE 61 STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 62 STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7.1 DRUG SUBSTANCE STABILITY TESTING
6.7.1.1 Regulatory requirements for drug approval to drive market
TABLE 63 DRUG SUBSTANCE STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7.2 FORMULATION EVALUATION STABILITY TESTING
6.7.2.1 Need to analyze and predict shelf life of products to drive demand
TABLE 64 FORMULATION EVALUATION STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7.3 ACCELERATED STABILITY TESTING
6.7.3.1 Growing use of accelerated stability testing to determine shelf life of pharmaceutical products to fuel growth
TABLE 65 ACCELERATED STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7.4 PHOTOSTABILITY TESTING
6.7.4.1 Need for robust photostability testing process to ensure product quality and safety to drive adoption
TABLE 66 PHOTOSTABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7.5 FORCED DEGRADATION TESTING
6.7.5.1 Regulatory requirements and need for comprehensive stability testing in pharmaceutical industry to boost market
TABLE 67 FORCED DEGRADATION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7.6 OTHER STABILITY TESTING SERVICES
TABLE 68 OTHER STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8 MICROBIAL TESTING
TABLE 69 MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 70 MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8.1 MICROBIAL LIMIT TESTING
6.8.1.1 Need to determine whether products comply with compendial specifications for microbial quality to boost adoption
TABLE 71 STANDARD LIMITS FOR MICROBIAL LIMIT TESTING
TABLE 72 MICROBIAL LIMIT TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8.2 VIROLOGY TESTING
6.8.2.1 Increasing outbreaks of viral diseases to drive market
TABLE 73 VIROLOGY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8.3 STERILITY TESTING
6.8.3.1 Rising development of parenteral preparations and immunological products to drive market
TABLE 74 STERILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8.4 ENDOTOXIN TESTING
6.8.4.1 Need to standardize procedures and follow regulatory guidelines to support demand
TABLE 75 ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8.5 PRESERVATIVE EFFICACY TESTING
6.8.5.1 Need to ensure product safety for product approval to support growth
TABLE 76 PRESERVATIVE EFFICACY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8.6 OTHER MICROBIAL TESTING SERVICES
TABLE 77 OTHER MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.9 GENOMIC TESTING SERVICES
6.9.1 NEED TO GAIN INSIGHTS INTO DISEASE MECHANISMS AND TREATMENT RESPONSES TO BOOST MARKET
TABLE 78 GENOMIC TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.10 OTHER ANALYTICAL TESTING SERVICES
TABLE 79 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER
7.1 INTRODUCTION
TABLE 80 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
7.2 PHARMACEUTICAL COMPANIES
7.2.1 INCREASED OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH
FIGURE 36 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2020–2022
TABLE 81 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
7.3 BIOPHARMACEUTICAL COMPANIES
7.3.1 GROWING INVESTMENTS IN BIOPHARMACEUTICAL COMPANIES TO BOOST MARKET GROWTH
TABLE 82 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
7.4 MEDICAL DEVICE COMPANIES
7.4.1 STRICT APPROVAL NORMS FOR MEDICAL DEVICES TO SUPPORT GROWTH
TABLE 83 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022–2029 (USD MILLION)
7.5 HOSPITALS & CLINICS
7.5.1 GROWING PREVALENCE OF CHRONIC DISEASES TO FAVOR MARKET GROWTH
TABLE 84 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)
7.6 FORENSIC LABS
7.6.1 GROWING USE OF ANALYTICAL TESTING IN FORENSIC LABS TO BOOST MARKET GROWTH
TABLE 85 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR FORENSIC LABS, BY REGION, 2022–2029 (USD MILLION)
7.7 COSMETIC & NUTRACEUTICAL COMPANIES
7.7.1 STRINGENT GUIDELINES FOR QUALITY CONTROL TO DRIVE MARKET
TABLE 86 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR COSMETIC & NUTRACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
8 HEALTHCARE ANALYTICAL TESTING MARKET, BY REGION
8.1 INTRODUCTION
FIGURE 37 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC SNAPSHOT
TABLE 87 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 38 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
TABLE 88 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 89 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 90 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 91 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 92 NORTH AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 93 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 94 NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 95 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 96 NORTH AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 97 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
8.2.2 US
8.2.2.1 High number of pre-registration drugs in pipeline to drive market
FIGURE 39 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2021)
TABLE 98 US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 99 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 100 US: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 101 US: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 102 US: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 103 US: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 104 US: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 105 US: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.2.3 CANADA
8.2.3.1 Presence of well-established CROs to support market growth
FIGURE 40 CANADA: ONGOING CLINICAL TRIALS, BY THERAPEUTIC AREA (2023)
TABLE 106 CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 107 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 108 CANADA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 109 CANADA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 110 CANADA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 111 CANADA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 112 CANADA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 113 CANADA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3 EUROPE
8.3.1 EUROPE: RECESSION IMPACT
TABLE 114 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 115 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 116 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 117 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 118 EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 119 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 120 EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 121 EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 122 EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 123 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
8.3.2 GERMANY
8.3.2.1 Government support and flexible labor laws make Germany favorable location for clinical trials
TABLE 124 GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 125 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 126 GERMANY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 127 GERMANY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 128 GERMANY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 129 GERMANY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 130 GERMANY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 131 GERMANY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Favorable government regulations to drive market
TABLE 132 FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 133 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 134 FRANCE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 135 FRANCE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 136 FRANCE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 137 FRANCE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 138 FRANCE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 139 FRANCE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3.4 UK
8.3.4.1 Investments by pharmaceutical sponsors for drug discovery services to support growth
TABLE 140 UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 141 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 142 UK: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 143 UK: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 144 UK: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 145 UK: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 146 UK: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 147 UK: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3.5 ITALY
8.3.5.1 Low drug approval time to support market growth
TABLE 148 ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 149 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 150 ITALY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 151 ITALY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 152 ITALY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 153 ITALY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 154 ITALY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 155 ITALY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3.6 SWITZERLAND
8.3.6.1 Large and growing pharma production volume to drive demand for analytical testing services
TABLE 156 SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 157 SWITZERLAND: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 158 SWITZERLAND: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 159 SWITZERLAND: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 160 SWITZERLAND: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 161 SWITZERLAND: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 162 SWITZERLAND: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 163 SWITZERLAND: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3.7 SPAIN
8.3.7.1 Rising R&D expenditure to boost growth
TABLE 164 SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 165 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 166 SPAIN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 167 SPAIN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 168 SPAIN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 169 SPAIN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 SPAIN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 171 SPAIN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3.8 REST OF EUROPE
TABLE 172 REST OF EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 173 REST OF EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 174 REST OF EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 175 REST OF EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 176 REST OF EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 177 REST OF EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 178 REST OF EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 179 REST OF EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 41 ASIA PACIFIC: HEALTHCARE ANALYTICS TESTING SERVICES MARKET SNAPSHOT
TABLE 180 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 181 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 182 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 183 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 184 ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 185 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 186 ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 187 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 188 ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 189 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Low manufacturing cost of medicines to drive demand
TABLE 190 CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 191 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 192 CHINA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 193 CHINA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 194 CHINA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 195 CHINA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 196 CHINA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 197 CHINA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.4.3 JAPAN
8.4.3.1 Rising geriatric population to support market growth
TABLE 198 JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 199 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 200 JAPAN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 201 JAPAN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 202 JAPAN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 203 JAPAN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 204 JAPAN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 205 JAPAN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.4.4 INDIA
8.4.4.1 Increasing number of clinical trials to drive market
TABLE 206 INDIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 207 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 208 INDIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 209 INDIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 INDIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 211 INDIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 212 INDIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 213 INDIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.4.5 AUSTRALIA
8.4.5.1 Large number of research institutes make Australia favorable location for drug discovery
TABLE 214 AUSTRALIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 215 AUSTRALIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 216 AUSTRALIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 217 AUSTRALIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 218 AUSTRALIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 219 AUSTRALIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 220 AUSTRALIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 221 AUSTRALIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.4.6 SOUTH KOREA
8.4.6.1 Growth in clinical trial activities to propel market
TABLE 222 SOUTH KOREA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 223 SOUTH KOREA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 224 SOUTH KOREA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 225 SOUTH KOREA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 226 SOUTH KOREA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 227 SOUTH KOREA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 228 SOUTH KOREA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 229 SOUTH KOREA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.4.7 REST OF ASIA PACIFIC
TABLE 230 REST OF ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 231 REST OF ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 232 REST OF ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 233 REST OF ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 234 REST OF ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 235 REST OF ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 236 REST OF ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 237 REST OF ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.5 LATIN AMERICA
8.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 238 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 239 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 240 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 241 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 242 LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 243 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 244 LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 245 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 246 LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 247 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
8.5.2 BRAZIL
8.5.2.1 Rising adoption of emerging medical technologies to drive market
TABLE 248 BRAZIL: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 249 BRAZIL: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 250 BRAZIL: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 251 BRAZIL: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 252 BRAZIL: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 253 BRAZIL: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 254 BRAZIL: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 255 BRAZIL: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.5.3 MEXICO
8.5.3.1 Government initiatives and robust supply to drive market
TABLE 256 MEXICO: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 257 MEXICO: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 258 MEXICO: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 259 MEXICO: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 260 MEXICO: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 261 MEXICO: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 262 MEXICO: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 263 MEXICO: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.5.4 REST OF LATIN AMERICA
TABLE 264 REST OF LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 265 REST OF LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 266 REST OF LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 267 REST OF LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 268 REST OF LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 269 REST OF LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 270 REST OF LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 271 REST OF LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.6 MIDDLE EAST & AFRICA
8.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 272 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 273 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 274 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 275 MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 276 MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 277 MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 278 MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 279 MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 280 MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 281 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
8.6.2 GCC
8.6.2.1 Supportive government initiatives to aid market growth
TABLE 282 GCC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 283 GCC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 284 GCC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 285 GCC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 286 GCC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 287 GCC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 288 GCC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 289 GCC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.6.3 REST OF MIDDLE EAST & AFRICA
TABLE 290 REST OF MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 291 REST OF MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 292 REST OF MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 293 REST OF MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 294 REST OF MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 295 REST OF MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 296 REST OF MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 297 REST OF MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 42 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: STRATEGIES ADOPTED
9.3 REVENUE SHARE ANALYSIS
FIGURE 43 REVENUE ANALYSIS FOR KEY PLAYERS (2018–2022)
9.4 MARKET SHARE ANALYSIS
FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 298 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEGREE OF COMPETITION
9.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
9.5.1 STARS
9.5.2 PERVASIVE PLAYERS
9.5.3 EMERGING LEADERS
9.5.4 PARTICIPANTS
FIGURE 45 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
9.5.5 COMPANY FOOTPRINT
9.5.5.1 Overall footprint
FIGURE 46 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: OVERALL FOOTPRINT
9.5.5.2 Service footprint
TABLE 299 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: SERVICE FOOTPRINT
9.5.5.3 End-user footprint
TABLE 300 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: END-USER FOOTPRINT
9.5.5.4 Regional footprint
TABLE 301 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: REGIONAL FOOTPRINT
9.6 COMPANY EVALUATION MATRIX: START-UPS/SMES
9.6.1 PROGRESSIVE COMPANIES
9.6.2 DYNAMIC COMPANIES
9.6.3 RESPONSIVE COMPANIES
9.6.4 STARTING BLOCKS
FIGURE 47 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
9.6.5 COMPETITIVE BENCHMARKING
TABLE 302 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 303 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
9.7 VALUATION AND FINANCIAL METRICS OF HEALTHCARE ANALYTICAL TESTING SERVICE VENDORS
FIGURE 48 EV/EBITDA OF KEY VENDORS
9.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 49 BRAND/PRODUCT COMPARATIVE ANALYSIS OF KEY PLAYERS, BY SERVICE TYPE
9.8.1 EUROFINS SCIENTIFIC
9.8.2 WUXI APPTEC
9.8.3 CHARLES RIVER LABORATORIES
9.8.4 SGS S.A.
9.8.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
9.9 COMPETITIVE SCENARIO
9.9.1 SERVICE LAUNCHES
TABLE 304 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2020–MARCH 2024
9.9.2 DEALS
TABLE 305 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEALS, JANUARY 2020–MARCH 2024
TABLE 306 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: EXPANSIONS, JANUARY 2020–MARCH 2024
10 COMPANY PROFILES
10.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 EUROFINS SCIENTIFIC
TABLE 307 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
FIGURE 50 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
TABLE 308 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 309 EUROFINS SCIENTIFIC: DEALS
10.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS
TABLE 310 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
FIGURE 51 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
TABLE 311 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 312 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS
TABLE 313 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS
10.1.3 WUXI APPTEC
TABLE 314 WUXI APPTEC: COMPANY OVERVIEW
FIGURE 52 WUXI APPTEC: COMPANY SNAPSHOT (2022)
TABLE 315 WUXI APPTEC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 316 WUXI APPTEC: SERVICE LAUNCHES
TABLE 317 WUXI APPTEC: DEALS
TABLE 318 WUXI APPTEC: EXPANSIONS
10.1.4 CHARLES RIVER LABORATORIES
TABLE 319 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)
TABLE 320 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 321 CHARLES RIVER LABORATORIES: SERVICE LAUNCHES
TABLE 322 CHARLES RIVER LABORATORIES: DEALS
10.1.5 SGS S.A.
TABLE 323 SGS S.A.: COMPANY OVERVIEW
FIGURE 54 SGS S.A.: COMPANY SNAPSHOT (2023)
TABLE 324 SGS S.A.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 325 SGS S.A.: DEALS
TABLE 326 SGS S.A.: OTHER DEVELOPMENTS
10.1.6 THERMO FISHER SCIENTIFIC INC.
TABLE 327 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 55 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
TABLE 328 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 329 THERMO FISHER SCIENTIFIC INC.: DEALS
TABLE 330 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS
10.1.7 MEDPACE, INC.
TABLE 331 MEDPACE, INC.: COMPANY OVERVIEW
FIGURE 56 MEDPACE, INC.: COMPANY SNAPSHOT (2022)
TABLE 332 MEDPACE, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
10.1.8 SARTORIUS AG
TABLE 333 SARTORIUS AG: COMPANY OVERVIEW
FIGURE 57 SARTORIUS AG: COMPANY SNAPSHOT (2022)
TABLE 334 SARTORIUS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 335 SARTORIUS AG: DEALS
10.1.9 INTERTEK GROUP PLC
TABLE 336 INTERTEK GROUP PLC: COMPANY OVERVIEW
FIGURE 58 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2022)
TABLE 337 INTERTEK GROUP PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 338 INTERTEK GROUP PLC: DEALS
TABLE 339 INTERTEK GROUP PLC: EXPANSIONS
10.1.10 MERCK KGAA
TABLE 340 MERCK KGAA: COMPANY OVERVIEW
FIGURE 59 MERCK KGAA: COMPANY SNAPSHOT (2022)
TABLE 341 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 342 MERCK KGAA: SERVICE LAUNCHES
TABLE 343 MERCK KGAA: DEALS
TABLE 344 MERCK KGAA: EXPANSIONS
TABLE 345 MERCK KGAA: OTHER DEVELOPMENTS
10.1.11 SOURCE BIOSCIENCE
TABLE 346 SOURCE BIOSCIENCE: COMPANY OVERVIEW
FIGURE 60 SOURCE BIOSCIENCE: COMPANY SNAPSHOT (2022)
TABLE 347 SOURCE BIOSCIENCE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 348 SOURCE BIOSCIENCE: SERVICE LAUNCHES
TABLE 349 SOURCE BIOSCIENCE: EXPANSIONS
10.1.12 ICON PLC
TABLE 350 ICON PLC: COMPANY OVERVIEW
FIGURE 61 ICON PLC: COMPANY SNAPSHOT (2022)
TABLE 351 ICON PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 352 ICON PLC: DEALS
10.1.13 ALS
TABLE 353 ALS: COMPANY OVERVIEW
FIGURE 62 ALS: COMPANY SNAPSHOT (2022)
TABLE 354 ALS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 355 ALS: DEALS
10.1.14 FRONTAGE LABORATORIES, INC.
TABLE 356 FRONTAGE LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 63 FRONTAGE LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
TABLE 357 FRONTAGE LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 358 FRONTAGE LABORATORIES, INC.: DEALS
TABLE 359 FRONTAGE LABORATORIES, INC.: OTHER DEVELOPMENTS
10.1.15 STERIS
TABLE 360 STERIS: COMPANY OVERVIEW
FIGURE 64 STERIS: COMPANY SNAPSHOT (2023)
TABLE 361 STERIS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
10.1.16 IQVIA INC.
TABLE 362 IQVIA INC.: COMPANY OVERVIEW
FIGURE 65 IQVIA INC.: COMPANY SNAPSHOT (2023)
TABLE 363 IQVIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 364 IQVIA INC.: OTHER DEVELOPMENTS
10.1.17 ELEMENT MATERIALS TECHNOLOGY
TABLE 365 ELEMENT MATERIALS TECHNOLOGY: COMPANY OVERVIEW
TABLE 366 ELEMENT MATERIALS TECHNOLOGY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 367 ELEMENT MATERIALS TECHNOLOGY: SERVICE LAUNCHES
TABLE 368 ELEMENT MATERIALS TECHNOLOGY: DEALS
TABLE 369 ELEMENT MATERIALS TECHNOLOGY: EXPANSIONS
10.1.18 PACE ANALYTICAL SERVICES
TABLE 370 PACE ANALYTICAL SERVICES: COMPANY OVERVIEW
TABLE 371 PACE ANALYTICAL SERVICES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 372 PACE ANALYTICAL SERVICES: DEALS
TABLE 373 PACE ANALYTICAL SERVICES: OTHER DEVELOPMENTS
10.1.19 ALMAC GROUP
TABLE 374 ALMAC GROUP: COMPANY OVERVIEW
TABLE 375 ALMAC GROUP: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 376 ALMAC GROUP: SERVICE LAUNCHES
TABLE 377 ALMAC GROUP: EXPANSIONS
10.1.20 PHARMARON
TABLE 378 PHARMARON: COMPANY OVERVIEW
TABLE 379 PHARMARON: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 380 PHARMARON: DEALS
10.2 OTHER PLAYERS
10.2.1 SYNEOS HEALTH
TABLE 381 SYNEOS HEALTH: COMPANY OVERVIEW
10.2.2 PAREXEL INTERNATIONAL (MA) CORPORATION
TABLE 382 PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW
10.2.3 LGC LIMITED
TABLE 383 LGC LIMITED: COMPANY OVERVIEW
10.2.4 CELERION
TABLE 384 CELERION: COMPANY OVERVIEW
10.2.5 BIOAGILYTIX
TABLE 385 BIOAGILYTIX: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.2.2 MARKET SEGMENTATION
FIGURE 1 MARKETS COVERED
1.2.3 REGIONS COVERED
FIGURE 2 REGIONAL SEGMENTATION
1.2.4 YEARS CONSIDERED
1.3 CURRENCY CONSIDERED
1.4 LIMITATIONS
1.4.1 METHODOLOGY-RELATED LIMITATIONS
1.4.2 SCOPE-RELATED LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH METHODOLOGY DESIGN
FIGURE 3 RESEARCH DESIGN
2.2.1 SECONDARY RESEARCH
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
FIGURE 4 PRIMARY SOURCES
2.2.2.1 Key data from primary sources
2.2.2.2 Insights from primary experts
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION METHODOLOGY
FIGURE 7 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 8 REVENUE SHARE ANALYSIS: COMPANY ILLUSTRATION
FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 10 TOP-DOWN APPROACH
FIGURE 11 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 12 CAGR PROJECTIONS
2.4 DATA TRIANGULATION PROCEDURE
FIGURE 13 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ESTIMATION
2.6 STUDY ASSUMPTIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT ANALYSIS
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 14 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 16 PHYSICAL CHARACTERIZATION TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 17 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
4 PREMIUM INSIGHTS
4.1 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET OVERVIEW
FIGURE 19 GROWING ADOPTION OF OUTSOURCED ANALYTICAL TESTING SERVICES BY PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES TO DRIVE GROWTH
4.2 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE AND COUNTRY (2023)
FIGURE 20 BIOANALYTICAL TESTING SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2023
4.3 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 CHINA, INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 REGIONAL MIX: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET (2022–2029)
FIGURE 22 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD (2022–2029)
4.5 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEVELOPED VS. EMERGING ECONOMIES (2024 VS. 2029)
FIGURE 23 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 24 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Stringent regulatory guidelines
5.2.1.2 Growing focus on analytical testing of biologics & biosimilars
TABLE 2 PATENT EXPIRY OF BEST-SELLING BIOLOGICS
5.2.1.3 Increasing outsourcing of analytical testing by pharmaceutical & medical device companies
5.2.1.4 Increasing number of clinical trials
FIGURE 25 INCREASING NUMBER OF CLINICAL TRIALS WORLDWIDE (2004–2024)
FIGURE 26 PERCENTAGE OF REGISTERED STUDIES BY LOCATION (AS OF MARCH 08, 2024)
5.2.1.5 Growing R&D expenditure in pharmaceutical & biopharmaceutical industry
FIGURE 27 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2002–2022
5.2.1.6 Rising acceptance of quality-by-design approach in pharmaceutical research & manufacturing
TABLE 3 IMPACT ANALYSIS: DRIVERS
5.2.2 RESTRAINTS
5.2.2.1 Increasing pressure on market players due to rising costs and market competition
TABLE 4 IMPACT ANALYSIS: RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.3.1 Adoption of new techniques and technologies
5.2.3.2 Growing focus on emerging economies
TABLE 5 IMPACT ANALYSIS: OPPORTUNITIES
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled professionals
5.2.4.2 Specific requirements for innovative formulations and medical devices
5.2.4.3 Need to improve sensitivity of bioanalytical methods
TABLE 6 IMPACT ANALYSIS: CHALLENGES
5.3 ECOSYSTEM ANALYSIS
TABLE 7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ROLE IN ECOSYSTEM
FIGURE 28 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ECOSYSTEM ANALYSIS
5.4 VALUE CHAIN ANALYSIS
FIGURE 29 VALUE CHAIN ANALYSIS
5.5 CASE STUDY ANALYSIS
5.5.1 UNLOCKING BIOPHARMACEUTICAL DEVELOPMENT POTENTIAL THROUGH OUTSOURCING ANALYTICAL TESTING
5.5.2 REVOLUTIONIZING PHARMACEUTICAL TESTING: A CASE STUDY IN ANALYTICAL TESTING EVOLUTION
5.6 PORTER’S FIVE FORCES ANALYSIS
TABLE 8 PORTER’S FIVE FORCES ANALYSIS
FIGURE 30 PORTER’S FIVE FORCES ANALYSIS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 BARGAINING POWER OF SUPPLIERS
5.6.3 INTENSITY OF COMPETITIVE RIVALRY
5.6.4 BARGAINING POWER OF BUYERS
5.6.5 THREAT OF SUBSTITUTES
5.7 REGULATORY LANDSCAPE
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.2 REGULATORY ANALYSIS
TABLE 14 ICH QUALITY GUIDELINES FOR PHARMACEUTICAL GMPS
TABLE 15 OVERVIEW OF GUIDELINES OF LABORATORY SERVICES
5.7.3 NORTH AMERICA
5.7.4 EUROPE
TABLE 16 DEVELOPMENT OF GLP ACROSS COUNTRIES
TABLE 17 REGULATORY AUTHORITIES AND LAUNCH OF GLP MONITORING PROGRAMS IN EUROPEAN COUNTRIES
5.7.5 ASIA PACIFIC
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 31 REVENUE SHIFT AND NEW POCKETS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
5.9 KEY CONFERENCES & EVENTS, 2024–2025
TABLE 18 HEALTHCARE ANALYTICAL TESTING MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.10 INVESTMENT AND FUNDING SCENARIO
FIGURE 32 NUMBER OF INVESTOR DEALS IN HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY KEY PLAYER, 2018–2022
FIGURE 33 VALUE OF INVESTOR DEALS IN HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY KEY PLAYER, 2018-2022
5.11 KEY STAKEHOLDERS & BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
5.11.2 BUYING CRITERIA
FIGURE 35 KEY BUYING CRITERIA FOR END USERS
TABLE 20 KEY BUYING CRITERIA FOR END USERS
6 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 21 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
6.2 BIOANALYTICAL TESTING
TABLE 22 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 23 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1 PHARMACOKINETIC & TOXICOKINETIC TESTING
6.2.1.1 Increasing number of clinical trials for drug development to propel growth
TABLE 24 PHARMACOKINETIC TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.2 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING
6.2.2.1 Increasing requirement for drug safety approvals to support market growth
TABLE 25 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.3 BIOMARKER TESTING
6.2.3.1 Rising need for specialized drug development to drive market
TABLE 26 BIOMARKER TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.4 BIOASSAY TESTING
6.2.4.1 Growing adoption of high-content screening for cytotoxicity testing to fuel growth
TABLE 27 BIOASSAY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.5 OTHER BIOANALYTICAL TESTING SERVICES
TABLE 28 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3 PHYSICAL CHARACTERIZATION
TABLE 29 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 30 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.1 LASER PARTICLE SIZE ANALYSIS
6.3.1.1 Growing importance of particle size analysis in manufacturing pharmaceutical dosage forms to drive market
TABLE 31 LASER PARTICLE SIZE ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.2 THERMAL ANALYSIS
6.3.2.1 Advancements in thermal analysis techniques to support growth
TABLE 32 THERMAL ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.3 OPTICAL CHARACTERIZATION
6.3.3.1 Growing complexity of biological structures to contribute to growth
TABLE 33 OPTICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.4 SURFACE AREA ANALYSIS
6.3.4.1 Growing need for surface analysis to streamline drug development processes to fuel growth
TABLE 34 SURFACE AREA ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.5 OTHER PHYSICAL CHARACTERIZATION SERVICES
TABLE 35 OTHER PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4 METHOD DEVELOPMENT & VALIDATION
TABLE 36 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 37 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.1 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION
6.4.1.1 Growing development of parenterally administered drugs and biologic products to drive market
TABLE 38 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.2 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION
6.4.2.1 Rising emphasis on impurity testing to boost market
TABLE 39 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.3 STABILITY-INDICATING METHOD VALIDATION
6.4.3.1 Need to ensure safety and efficacy of therapeutic drugs to spur growth
TABLE 40 STABILITY-INDICATING METHOD VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.4 CLEANING VALIDATION & METHOD DEVELOPMENT
6.4.4.1 Growing needs to evaluate cleaning practices and ensure complete decontamination to fuel growth
TABLE 41 CLEANING VALIDATION & METHOD DEVELOPMENT SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.5 ANALYTICAL STANDARD CHARACTERIZATION
6.4.5.1 Growing importance of analytical standard characterization in drug development to support market
TABLE 42 ANALYTICAL STANDARD CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.6 TECHNICAL CONSULTING
6.4.6.1 Need for regulatory approvals for drug development to drive market
TABLE 43 TECHNICAL CONSULTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4.7 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES
TABLE 44 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5 RAW MATERIAL TESTING
TABLE 45 RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 46 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5.1 COMPLETE COMPENDIAL TESTING
6.5.1.1 Need to determine efficacy and safety of therapeutic products to drive growth
TABLE 47 COMPLETE COMPENDIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5.2 CONTAINER TESTING
6.5.2.1 Need to optimize sealing and evaluate temperature impact to fuel growth
TABLE 48 CONTAINER TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5.3 HEAVY METAL TESTING
6.5.3.1 Implementation of various techniques and technologies for heavy metal testing to aid growth
TABLE 49 HEAVY METAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5.4 WATER CONTENT ANALYSIS
6.5.4.1 Need to check for water content in pharmaceutical products to support growth
TABLE 50 WATER CONTENT ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5.5 OTHER RAW MATERIAL TESTING SERVICES
TABLE 51 OTHER RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6 BATCH-RELEASE TESTING SERVICES
TABLE 52 BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 53 BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6.1 DISSOLUTION TESTING
6.6.1.1 Wide usage of dissolution testing in formulation development and manufacturing to drive growth
TABLE 54 DISSOLUTION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6.2 ELEMENTAL IMPURITY TESTING
6.6.2.1 Need to minimize cost of in-house analysis and labor to fuel growth
TABLE 55 ELEMENTAL IMPURITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6.3 DISINTEGRATION TESTING
6.6.3.1 Need to ensure batch-to-batch consistency of pharmaceutical dosage forms to promote growth
TABLE 56 BREAKDOWN OF DISINTEGRATION METHODS AND IMMERSION MEDIA
TABLE 57 DISINTEGRATION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6.4 HARDNESS TESTING
6.6.4.1 Need to assess manufacturability and compactness of pharmaceutical formulations to ensure growth
TABLE 58 HARDNESS TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6.5 FRIABILITY TESTING
6.6.5.1 Need to measure resistance of tablets and granules to abrasion or fracture to support market
TABLE 59 FRIABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6.6 OTHER BATCH-RELEASE TESTING SERVICES
TABLE 60 OTHER BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7 STABILITY TESTING
TABLE 61 STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 62 STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7.1 DRUG SUBSTANCE STABILITY TESTING
6.7.1.1 Regulatory requirements for drug approval to drive market
TABLE 63 DRUG SUBSTANCE STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7.2 FORMULATION EVALUATION STABILITY TESTING
6.7.2.1 Need to analyze and predict shelf life of products to drive demand
TABLE 64 FORMULATION EVALUATION STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7.3 ACCELERATED STABILITY TESTING
6.7.3.1 Growing use of accelerated stability testing to determine shelf life of pharmaceutical products to fuel growth
TABLE 65 ACCELERATED STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7.4 PHOTOSTABILITY TESTING
6.7.4.1 Need for robust photostability testing process to ensure product quality and safety to drive adoption
TABLE 66 PHOTOSTABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7.5 FORCED DEGRADATION TESTING
6.7.5.1 Regulatory requirements and need for comprehensive stability testing in pharmaceutical industry to boost market
TABLE 67 FORCED DEGRADATION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.7.6 OTHER STABILITY TESTING SERVICES
TABLE 68 OTHER STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8 MICROBIAL TESTING
TABLE 69 MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 70 MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8.1 MICROBIAL LIMIT TESTING
6.8.1.1 Need to determine whether products comply with compendial specifications for microbial quality to boost adoption
TABLE 71 STANDARD LIMITS FOR MICROBIAL LIMIT TESTING
TABLE 72 MICROBIAL LIMIT TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8.2 VIROLOGY TESTING
6.8.2.1 Increasing outbreaks of viral diseases to drive market
TABLE 73 VIROLOGY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8.3 STERILITY TESTING
6.8.3.1 Rising development of parenteral preparations and immunological products to drive market
TABLE 74 STERILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8.4 ENDOTOXIN TESTING
6.8.4.1 Need to standardize procedures and follow regulatory guidelines to support demand
TABLE 75 ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8.5 PRESERVATIVE EFFICACY TESTING
6.8.5.1 Need to ensure product safety for product approval to support growth
TABLE 76 PRESERVATIVE EFFICACY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.8.6 OTHER MICROBIAL TESTING SERVICES
TABLE 77 OTHER MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.9 GENOMIC TESTING SERVICES
6.9.1 NEED TO GAIN INSIGHTS INTO DISEASE MECHANISMS AND TREATMENT RESPONSES TO BOOST MARKET
TABLE 78 GENOMIC TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.10 OTHER ANALYTICAL TESTING SERVICES
TABLE 79 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER
7.1 INTRODUCTION
TABLE 80 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
7.2 PHARMACEUTICAL COMPANIES
7.2.1 INCREASED OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH
FIGURE 36 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2020–2022
TABLE 81 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
7.3 BIOPHARMACEUTICAL COMPANIES
7.3.1 GROWING INVESTMENTS IN BIOPHARMACEUTICAL COMPANIES TO BOOST MARKET GROWTH
TABLE 82 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
7.4 MEDICAL DEVICE COMPANIES
7.4.1 STRICT APPROVAL NORMS FOR MEDICAL DEVICES TO SUPPORT GROWTH
TABLE 83 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022–2029 (USD MILLION)
7.5 HOSPITALS & CLINICS
7.5.1 GROWING PREVALENCE OF CHRONIC DISEASES TO FAVOR MARKET GROWTH
TABLE 84 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)
7.6 FORENSIC LABS
7.6.1 GROWING USE OF ANALYTICAL TESTING IN FORENSIC LABS TO BOOST MARKET GROWTH
TABLE 85 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR FORENSIC LABS, BY REGION, 2022–2029 (USD MILLION)
7.7 COSMETIC & NUTRACEUTICAL COMPANIES
7.7.1 STRINGENT GUIDELINES FOR QUALITY CONTROL TO DRIVE MARKET
TABLE 86 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR COSMETIC & NUTRACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
8 HEALTHCARE ANALYTICAL TESTING MARKET, BY REGION
8.1 INTRODUCTION
FIGURE 37 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC SNAPSHOT
TABLE 87 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 38 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
TABLE 88 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 89 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 90 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 91 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 92 NORTH AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 93 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 94 NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 95 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 96 NORTH AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 97 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
8.2.2 US
8.2.2.1 High number of pre-registration drugs in pipeline to drive market
FIGURE 39 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2021)
TABLE 98 US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 99 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 100 US: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 101 US: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 102 US: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 103 US: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 104 US: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 105 US: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.2.3 CANADA
8.2.3.1 Presence of well-established CROs to support market growth
FIGURE 40 CANADA: ONGOING CLINICAL TRIALS, BY THERAPEUTIC AREA (2023)
TABLE 106 CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 107 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 108 CANADA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 109 CANADA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 110 CANADA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 111 CANADA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 112 CANADA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 113 CANADA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3 EUROPE
8.3.1 EUROPE: RECESSION IMPACT
TABLE 114 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 115 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 116 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 117 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 118 EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 119 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 120 EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 121 EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 122 EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 123 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
8.3.2 GERMANY
8.3.2.1 Government support and flexible labor laws make Germany favorable location for clinical trials
TABLE 124 GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 125 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 126 GERMANY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 127 GERMANY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 128 GERMANY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 129 GERMANY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 130 GERMANY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 131 GERMANY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Favorable government regulations to drive market
TABLE 132 FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 133 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 134 FRANCE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 135 FRANCE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 136 FRANCE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 137 FRANCE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 138 FRANCE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 139 FRANCE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3.4 UK
8.3.4.1 Investments by pharmaceutical sponsors for drug discovery services to support growth
TABLE 140 UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 141 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 142 UK: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 143 UK: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 144 UK: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 145 UK: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 146 UK: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 147 UK: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3.5 ITALY
8.3.5.1 Low drug approval time to support market growth
TABLE 148 ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 149 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 150 ITALY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 151 ITALY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 152 ITALY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 153 ITALY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 154 ITALY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 155 ITALY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3.6 SWITZERLAND
8.3.6.1 Large and growing pharma production volume to drive demand for analytical testing services
TABLE 156 SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 157 SWITZERLAND: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 158 SWITZERLAND: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 159 SWITZERLAND: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 160 SWITZERLAND: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 161 SWITZERLAND: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 162 SWITZERLAND: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 163 SWITZERLAND: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3.7 SPAIN
8.3.7.1 Rising R&D expenditure to boost growth
TABLE 164 SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 165 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 166 SPAIN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 167 SPAIN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 168 SPAIN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 169 SPAIN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 SPAIN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 171 SPAIN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.3.8 REST OF EUROPE
TABLE 172 REST OF EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 173 REST OF EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 174 REST OF EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 175 REST OF EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 176 REST OF EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 177 REST OF EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 178 REST OF EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 179 REST OF EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 41 ASIA PACIFIC: HEALTHCARE ANALYTICS TESTING SERVICES MARKET SNAPSHOT
TABLE 180 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 181 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 182 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 183 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 184 ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 185 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 186 ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 187 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 188 ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 189 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Low manufacturing cost of medicines to drive demand
TABLE 190 CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 191 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 192 CHINA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 193 CHINA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 194 CHINA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 195 CHINA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 196 CHINA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 197 CHINA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.4.3 JAPAN
8.4.3.1 Rising geriatric population to support market growth
TABLE 198 JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 199 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 200 JAPAN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 201 JAPAN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 202 JAPAN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 203 JAPAN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 204 JAPAN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 205 JAPAN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.4.4 INDIA
8.4.4.1 Increasing number of clinical trials to drive market
TABLE 206 INDIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 207 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 208 INDIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 209 INDIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 INDIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 211 INDIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 212 INDIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 213 INDIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.4.5 AUSTRALIA
8.4.5.1 Large number of research institutes make Australia favorable location for drug discovery
TABLE 214 AUSTRALIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 215 AUSTRALIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 216 AUSTRALIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 217 AUSTRALIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 218 AUSTRALIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 219 AUSTRALIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 220 AUSTRALIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 221 AUSTRALIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.4.6 SOUTH KOREA
8.4.6.1 Growth in clinical trial activities to propel market
TABLE 222 SOUTH KOREA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 223 SOUTH KOREA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 224 SOUTH KOREA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 225 SOUTH KOREA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 226 SOUTH KOREA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 227 SOUTH KOREA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 228 SOUTH KOREA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 229 SOUTH KOREA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.4.7 REST OF ASIA PACIFIC
TABLE 230 REST OF ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 231 REST OF ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 232 REST OF ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 233 REST OF ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 234 REST OF ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 235 REST OF ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 236 REST OF ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 237 REST OF ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.5 LATIN AMERICA
8.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 238 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 239 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 240 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 241 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 242 LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 243 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 244 LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 245 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 246 LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 247 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
8.5.2 BRAZIL
8.5.2.1 Rising adoption of emerging medical technologies to drive market
TABLE 248 BRAZIL: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 249 BRAZIL: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 250 BRAZIL: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 251 BRAZIL: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 252 BRAZIL: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 253 BRAZIL: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 254 BRAZIL: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 255 BRAZIL: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.5.3 MEXICO
8.5.3.1 Government initiatives and robust supply to drive market
TABLE 256 MEXICO: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 257 MEXICO: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 258 MEXICO: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 259 MEXICO: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 260 MEXICO: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 261 MEXICO: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 262 MEXICO: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 263 MEXICO: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.5.4 REST OF LATIN AMERICA
TABLE 264 REST OF LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 265 REST OF LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 266 REST OF LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 267 REST OF LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 268 REST OF LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 269 REST OF LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 270 REST OF LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 271 REST OF LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.6 MIDDLE EAST & AFRICA
8.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 272 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 273 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 274 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 275 MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 276 MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 277 MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 278 MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 279 MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 280 MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 281 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
8.6.2 GCC
8.6.2.1 Supportive government initiatives to aid market growth
TABLE 282 GCC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 283 GCC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 284 GCC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 285 GCC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 286 GCC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 287 GCC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 288 GCC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 289 GCC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
8.6.3 REST OF MIDDLE EAST & AFRICA
TABLE 290 REST OF MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 291 REST OF MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 292 REST OF MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 293 REST OF MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 294 REST OF MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 295 REST OF MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 296 REST OF MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 297 REST OF MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 42 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: STRATEGIES ADOPTED
9.3 REVENUE SHARE ANALYSIS
FIGURE 43 REVENUE ANALYSIS FOR KEY PLAYERS (2018–2022)
9.4 MARKET SHARE ANALYSIS
FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 298 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEGREE OF COMPETITION
9.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
9.5.1 STARS
9.5.2 PERVASIVE PLAYERS
9.5.3 EMERGING LEADERS
9.5.4 PARTICIPANTS
FIGURE 45 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
9.5.5 COMPANY FOOTPRINT
9.5.5.1 Overall footprint
FIGURE 46 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: OVERALL FOOTPRINT
9.5.5.2 Service footprint
TABLE 299 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: SERVICE FOOTPRINT
9.5.5.3 End-user footprint
TABLE 300 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: END-USER FOOTPRINT
9.5.5.4 Regional footprint
TABLE 301 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: REGIONAL FOOTPRINT
9.6 COMPANY EVALUATION MATRIX: START-UPS/SMES
9.6.1 PROGRESSIVE COMPANIES
9.6.2 DYNAMIC COMPANIES
9.6.3 RESPONSIVE COMPANIES
9.6.4 STARTING BLOCKS
FIGURE 47 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
9.6.5 COMPETITIVE BENCHMARKING
TABLE 302 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 303 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
9.7 VALUATION AND FINANCIAL METRICS OF HEALTHCARE ANALYTICAL TESTING SERVICE VENDORS
FIGURE 48 EV/EBITDA OF KEY VENDORS
9.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 49 BRAND/PRODUCT COMPARATIVE ANALYSIS OF KEY PLAYERS, BY SERVICE TYPE
9.8.1 EUROFINS SCIENTIFIC
9.8.2 WUXI APPTEC
9.8.3 CHARLES RIVER LABORATORIES
9.8.4 SGS S.A.
9.8.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
9.9 COMPETITIVE SCENARIO
9.9.1 SERVICE LAUNCHES
TABLE 304 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2020–MARCH 2024
9.9.2 DEALS
TABLE 305 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEALS, JANUARY 2020–MARCH 2024
TABLE 306 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: EXPANSIONS, JANUARY 2020–MARCH 2024
10 COMPANY PROFILES
10.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 EUROFINS SCIENTIFIC
TABLE 307 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
FIGURE 50 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
TABLE 308 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 309 EUROFINS SCIENTIFIC: DEALS
10.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS
TABLE 310 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
FIGURE 51 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
TABLE 311 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 312 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS
TABLE 313 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS
10.1.3 WUXI APPTEC
TABLE 314 WUXI APPTEC: COMPANY OVERVIEW
FIGURE 52 WUXI APPTEC: COMPANY SNAPSHOT (2022)
TABLE 315 WUXI APPTEC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 316 WUXI APPTEC: SERVICE LAUNCHES
TABLE 317 WUXI APPTEC: DEALS
TABLE 318 WUXI APPTEC: EXPANSIONS
10.1.4 CHARLES RIVER LABORATORIES
TABLE 319 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)
TABLE 320 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 321 CHARLES RIVER LABORATORIES: SERVICE LAUNCHES
TABLE 322 CHARLES RIVER LABORATORIES: DEALS
10.1.5 SGS S.A.
TABLE 323 SGS S.A.: COMPANY OVERVIEW
FIGURE 54 SGS S.A.: COMPANY SNAPSHOT (2023)
TABLE 324 SGS S.A.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 325 SGS S.A.: DEALS
TABLE 326 SGS S.A.: OTHER DEVELOPMENTS
10.1.6 THERMO FISHER SCIENTIFIC INC.
TABLE 327 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 55 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
TABLE 328 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 329 THERMO FISHER SCIENTIFIC INC.: DEALS
TABLE 330 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS
10.1.7 MEDPACE, INC.
TABLE 331 MEDPACE, INC.: COMPANY OVERVIEW
FIGURE 56 MEDPACE, INC.: COMPANY SNAPSHOT (2022)
TABLE 332 MEDPACE, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
10.1.8 SARTORIUS AG
TABLE 333 SARTORIUS AG: COMPANY OVERVIEW
FIGURE 57 SARTORIUS AG: COMPANY SNAPSHOT (2022)
TABLE 334 SARTORIUS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 335 SARTORIUS AG: DEALS
10.1.9 INTERTEK GROUP PLC
TABLE 336 INTERTEK GROUP PLC: COMPANY OVERVIEW
FIGURE 58 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2022)
TABLE 337 INTERTEK GROUP PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 338 INTERTEK GROUP PLC: DEALS
TABLE 339 INTERTEK GROUP PLC: EXPANSIONS
10.1.10 MERCK KGAA
TABLE 340 MERCK KGAA: COMPANY OVERVIEW
FIGURE 59 MERCK KGAA: COMPANY SNAPSHOT (2022)
TABLE 341 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 342 MERCK KGAA: SERVICE LAUNCHES
TABLE 343 MERCK KGAA: DEALS
TABLE 344 MERCK KGAA: EXPANSIONS
TABLE 345 MERCK KGAA: OTHER DEVELOPMENTS
10.1.11 SOURCE BIOSCIENCE
TABLE 346 SOURCE BIOSCIENCE: COMPANY OVERVIEW
FIGURE 60 SOURCE BIOSCIENCE: COMPANY SNAPSHOT (2022)
TABLE 347 SOURCE BIOSCIENCE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 348 SOURCE BIOSCIENCE: SERVICE LAUNCHES
TABLE 349 SOURCE BIOSCIENCE: EXPANSIONS
10.1.12 ICON PLC
TABLE 350 ICON PLC: COMPANY OVERVIEW
FIGURE 61 ICON PLC: COMPANY SNAPSHOT (2022)
TABLE 351 ICON PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 352 ICON PLC: DEALS
10.1.13 ALS
TABLE 353 ALS: COMPANY OVERVIEW
FIGURE 62 ALS: COMPANY SNAPSHOT (2022)
TABLE 354 ALS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 355 ALS: DEALS
10.1.14 FRONTAGE LABORATORIES, INC.
TABLE 356 FRONTAGE LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 63 FRONTAGE LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
TABLE 357 FRONTAGE LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 358 FRONTAGE LABORATORIES, INC.: DEALS
TABLE 359 FRONTAGE LABORATORIES, INC.: OTHER DEVELOPMENTS
10.1.15 STERIS
TABLE 360 STERIS: COMPANY OVERVIEW
FIGURE 64 STERIS: COMPANY SNAPSHOT (2023)
TABLE 361 STERIS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
10.1.16 IQVIA INC.
TABLE 362 IQVIA INC.: COMPANY OVERVIEW
FIGURE 65 IQVIA INC.: COMPANY SNAPSHOT (2023)
TABLE 363 IQVIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 364 IQVIA INC.: OTHER DEVELOPMENTS
10.1.17 ELEMENT MATERIALS TECHNOLOGY
TABLE 365 ELEMENT MATERIALS TECHNOLOGY: COMPANY OVERVIEW
TABLE 366 ELEMENT MATERIALS TECHNOLOGY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 367 ELEMENT MATERIALS TECHNOLOGY: SERVICE LAUNCHES
TABLE 368 ELEMENT MATERIALS TECHNOLOGY: DEALS
TABLE 369 ELEMENT MATERIALS TECHNOLOGY: EXPANSIONS
10.1.18 PACE ANALYTICAL SERVICES
TABLE 370 PACE ANALYTICAL SERVICES: COMPANY OVERVIEW
TABLE 371 PACE ANALYTICAL SERVICES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 372 PACE ANALYTICAL SERVICES: DEALS
TABLE 373 PACE ANALYTICAL SERVICES: OTHER DEVELOPMENTS
10.1.19 ALMAC GROUP
TABLE 374 ALMAC GROUP: COMPANY OVERVIEW
TABLE 375 ALMAC GROUP: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 376 ALMAC GROUP: SERVICE LAUNCHES
TABLE 377 ALMAC GROUP: EXPANSIONS
10.1.20 PHARMARON
TABLE 378 PHARMARON: COMPANY OVERVIEW
TABLE 379 PHARMARON: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 380 PHARMARON: DEALS
10.2 OTHER PLAYERS
10.2.1 SYNEOS HEALTH
TABLE 381 SYNEOS HEALTH: COMPANY OVERVIEW
10.2.2 PAREXEL INTERNATIONAL (MA) CORPORATION
TABLE 382 PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW
10.2.3 LGC LIMITED
TABLE 383 LGC LIMITED: COMPANY OVERVIEW
10.2.4 CELERION
TABLE 384 CELERION: COMPANY OVERVIEW
10.2.5 BIOAGILYTIX
TABLE 385 BIOAGILYTIX: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
